Rui‐Hua Xu

1.4k total papers · 52.4k total citations
844 papers, 27.6k citations indexed

About

Rui‐Hua Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Rui‐Hua Xu has authored 844 papers receiving a total of 27.6k indexed citations (citations by other indexed papers that have themselves been cited), including 388 papers in Oncology, 263 papers in Pulmonary and Respiratory Medicine and 226 papers in Molecular Biology. Recurrent topics in Rui‐Hua Xu's work include Gastric Cancer Management and Outcomes (169 papers), Colorectal Cancer Treatments and Studies (160 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Rui‐Hua Xu is often cited by papers focused on Gastric Cancer Management and Outcomes (169 papers), Colorectal Cancer Treatments and Studies (160 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Rui‐Hua Xu collaborates with scholars based in China, United States and Japan. Rui‐Hua Xu's co-authors include Huai‐Qiang Ju, Hélène Pelicano, Su‐Mei Cao, De‐Shen Wang, Miao‐Zhen Qiu, Hui Luo, Zhao-Lei Zeng, Peng Huang, Ping Huang and Feng Wang and has published in prestigious journals such as Cell, The Lancet and Nucleic Acids Research.

In The Last Decade

Rui‐Hua Xu

787 papers receiving 27.3k citations

Hit Papers

Current cancer situation ... 2005 2026 2012 2019 2019 2006 2020 2005 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
    2019 1.2k citations Rui‐Hua Xu et al. Cancer Communications profile →
  2. Glycolysis inhibition for anticancer treatment
    2006 1.2k citations Hélène Pelicano, Rui‐Hua Xu et al. Oncogene profile →
  3. Circular RNA: metabolism, functions and interactions with proteins
    2020 829 citations Zerong Cai, Jia Liu et al. Molecular Cancer profile →
  4. Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia
    2005 698 citations Rui‐Hua Xu, Hélène Pelicano et al. Cancer Research profile →
  5. METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
    2019 602 citations Ting Li, Zhixiang Zuo et al. Molecular Cancer profile →
  6. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020
    2021 574 citations Haibo Qiu, Rui‐Hua Xu et al. Cancer Communications profile →
  7. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 548 citations Jin Li, Shukui Qin et al. The Lancet Oncology profile →
  8. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis
    2019 535 citations Rixin Chen, Xin Chen et al. Nature Communications profile →
  9. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
    2014 468 citations Rui‐Hua Xu, Hyun Cheol Chung et al. Journal of Clinical Oncology profile →
  10. LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
    2020 466 citations Jin‐Fei Lin, Ting Li et al. Cancer Communications profile →
  11. Gastric cancer treatment: recent progress and future perspectives
    2023 397 citations Wen‐Long Guan, Ye He et al. Journal of Hematology & Oncology profile →
  12. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
    2019 371 citations Yun Wang, Jia-Huan Lu et al. Molecular Cancer profile →
  13. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
    2020 361 citations Huai‐Qiang Ju, Jin‐Fei Lin et al. Signal Transduction and Targeted Therapy profile →
  14. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
    2023 320 citations Kohei Shitara, Florian Lordick et al. The Lancet profile →
  15. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
    2019 278 citations Feng Wang, Qi Zhao et al. JAMA Oncology profile →
  16. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis
    2022 221 citations Jin‐Fei Lin, Peishan Hu et al. Signal Transduction and Targeted Therapy profile →
  17. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA
    2021 203 citations Hui Luo, Wei Wei et al. Trends in Molecular Medicine profile →
  18. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response
    2022 161 citations Zhen Zhang, Zixian Wang et al. Genome Medicine profile →
  19. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study
    2023 76 citations Gong Chen, Ying Jin et al. ˜The œLancet. Gastroenterology & hepatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Rui‐Hua Xu 12.9k 9.6k 9.5k 6.3k 3.8k 844 27.6k
David S. Hong 9.5k 0.7× 10.4k 1.1× 5.8k 0.6× 6.2k 1.0× 2.1k 0.6× 816 23.0k
Manuel Hidalgo 12.5k 1.0× 18.4k 1.9× 7.4k 0.8× 7.0k 1.1× 3.1k 0.8× 447 29.6k
Hiroyuki Aburatani 24.3k 1.9× 8.4k 0.9× 7.6k 0.8× 6.0k 1.0× 3.6k 1.0× 531 37.9k
Giampaolo Tortora 9.9k 0.8× 13.8k 1.4× 4.7k 0.5× 7.8k 1.2× 2.5k 0.7× 636 24.3k
Camillo Porta 10.6k 0.8× 7.1k 0.7× 6.0k 0.6× 12.2k 1.9× 2.4k 0.6× 575 21.9k
Ming‐Sound Tsao 16.5k 1.3× 15.2k 1.6× 8.3k 0.9× 13.8k 2.2× 3.0k 0.8× 650 37.0k
Scott M. Lippman 13.5k 1.0× 12.8k 1.3× 7.9k 0.8× 10.6k 1.7× 4.8k 1.3× 528 37.1k
Waun Ki Hong 16.8k 1.3× 12.7k 1.3× 5.5k 0.6× 8.1k 1.3× 4.3k 1.1× 514 34.0k
Yasushi Yatabe 12.0k 0.9× 14.6k 1.5× 8.7k 0.9× 15.2k 2.4× 3.5k 0.9× 640 31.7k
Manfred Dietel 12.3k 1.0× 10.9k 1.1× 6.3k 0.7× 5.1k 0.8× 3.0k 0.8× 529 26.1k

Countries citing papers authored by Rui‐Hua Xu

Since Specialization
Citations

This map shows the geographic impact of Rui‐Hua Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rui‐Hua Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rui‐Hua Xu more than expected).

Fields of papers citing papers by Rui‐Hua Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rui‐Hua Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rui‐Hua Xu. The network helps show where Rui‐Hua Xu may publish in the future.

Co-authorship network of co-authors of Rui‐Hua Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Rui‐Hua Xu. A scholar is included among the top collaborators of Rui‐Hua Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rui‐Hua Xu. Rui‐Hua Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yung Hyun Choi Breakdown of academic impact, for papers by J. D. Thompson Breakdown of academic impact, for papers by David M. Goldenberg Breakdown of academic impact, for papers by César Fernández‐de‐las‐Peñas Breakdown of academic impact, for papers by Yan Li Breakdown of academic impact, for papers by Gordon Parker Breakdown of academic impact, for papers by Hiroyasu Iso Breakdown of academic impact, for papers by Seung Up Kim
Rankless by CCL
2026